COMPLETED

NUTIDE:302 - PART 3 / NUFOX + bevacizumab

COLORECTAL CANCER - PHASE 2 STUDY

Designed to assess NUFOX in combination with bevacizumab in the second-line setting

Key Eligibility Criteria

- Second-line patients with advanced colorectal cancer
- Received 1 prior fluoropyrimidine-based regimen

NUFIRI Q1W + bevacizumab

NUFOX Q1W **+ bevacizumab**

Objectives
- Establish safety of NUFOX in combination with bevacizumab

Key endpoints
- Safety & tolerability
- Anti-tumor activity
- PK

Patient population
- Second-line with 1 prior fluoropyrimidine-based regimen

NUFOX + bevacizumab

Number of patients	Age (median)	Prior chemotherapy regimens (median)*
6	64 (range 37-72)	1

Sex	Male Female	3 (50%) 3 (50%)
ECOG PS	0 1	0 6 (100%)
Metastatic sites, n	≤3 ≥4	1 (17%) 5 (83%)
Liver metastases	Yes	3 (50%)
RAS mutated	Yes No	3 (50%) 3 (50%)
Prior bev	Yes	0

REF Below

*for metastatic disease

NUFOX is well tolerated in combination with bevacizumab

	NUFOX + bevacizumab (n=6)		
	All Grades, n(%)	Grade 3, n(%)	Grade 4, n(%)
Diarrhea	5 (83%)	0	0
Nausea	6 (100%)	1 (17%)	0
Anemia	1 (17%)	0	0
Fatigue	3 (50%)	0	0
Flushing	3 (50%)	0	0
Vomiting	3 (50%)	1 (17%)	0
Abdominal pain	2 (33%)	0	0
Constipation	2 (33%)	0	0
Decreased appetite	2 (33%)	0	0
Dysguesia	1 (17%)	0	0
Platelet count decreased	1 (17%)	0	0
Headache	3 (50%)	0	0
Dizziness	2 (33%)	0	0

All Grade treatment related AEs with an incidence of ≥10% in NUC-3373 +/- combinations

- No Grade 4 toxicities
- Low rates of Grade 3 toxicities
- Encouraging safety profile compared to FOLFOX-based regimens
- RP2D: NUC-3373 1875 mg/m^2 + LV 400 mg/m^2 (Q1W) + oxaliplatin 85 mg/m^2 + bevacizumab 5 mg/kg (Q2W)

Khan *et al* (2023) Mol Cancer Ther; 22: Suppl 12 Abstract ID B048 (AACR NCI EORTC October 2023). Data cut-off: August 22, 2023

Encouraging anti-tumor activity in second-line patients



- Tumor shrinkages were observed in all patients
- Shrinkage of liver metastases (-4%, -14%) were observed in 2 of these patients

Encouraging PFS in second-line patients

- PFS typically decreases by 50% with each line of therapy in CRC patients
- Matching or exceeding the PFS achieved in the 1st line is a very encouraging sign of efficacy



Standard fluoropyrimidine based CRC regimens ~5 months longer PFS in 1st vs 2nd line
Data cut-off August 22, 2023

*switched to NUFIRI-bev due to oxaliplatin-related infusion reaction

- Majority of patients achieved PFS >5 months with 3 patients remaining on therapy

Key takeaways

NUFOX + bevacizumab has shown prolonged disease control & tumor reductions

NUFOX-bev has a favorable safety profile

NUC-3373 can be dosed over 2.5 hours as part of NUFOX + bevacizumab regimen